FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005021430> ?p ?o ?g. }

• W2005021430 endingPage "539" @default.
• W2005021430 startingPage "532" @default.
• W2005021430 abstract "This study evaluated the efficacy and toxicity of proton therapy for functional pituitary adenomas (FPAs).We analyzed 165 patients with FPAs who were treated at a single institution with proton therapy between 1992 and 2012 and had at least 6 months of follow-up. All but 3 patients underwent prior resection, and 14 received prior photon irradiation. Proton stereotactic radiosurgery was used for 92% of patients, with a median dose of 20 Gy(RBE). The remainder received fractionated stereotactic proton therapy. Time to biochemical complete response (CR, defined as ≥ 3 months of normal laboratory values with no medical treatment), local control, and adverse effects are reported.With a median follow-up time of 4.3 years (range, 0.5-20.6 years) for 144 evaluable patients, the actuarial 3-year CR rate and the median time to CR were 54% and 32 months among 74 patients with Cushing disease (CD), 63% and 27 months among 8 patients with Nelson syndrome (NS), 26% and 62 months among 50 patients with acromegaly, and 22% and 60 months among 9 patients with prolactinomas, respectively. One of 3 patients with thyroid stimulating hormone-secreting tumors achieved CR. Actuarial time to CR was significantly shorter for corticotroph FPAs (CD/NS) compared with other subtypes (P=.001). At a median imaging follow-up time of 43 months, tumor control was 98% among 140 patients. The actuarial 3-year and 5-year rates of development of new hypopituitarism were 45% and 62%, and the median time to deficiency was 40 months. Larger radiosurgery target volume as a continuous variable was a significant predictor of hypopituitarism (adjusted hazard ratio 1.3, P=.004). Four patients had new-onset postradiosurgery seizures suspected to be related to generously defined target volumes. There were no radiation-induced tumors.Proton irradiation is an effective treatment for FPAs, and hypopituitarism remains the primary adverse effect." @default.
• W2005021430 created "2016-06-24" @default.
• W2005021430 creator A5001528733 @default.
• W2005021430 creator A5003790985 @default.
• W2005021430 creator A5009874528 @default.
• W2005021430 creator A5017047283 @default.
• W2005021430 creator A5022118831 @default.
• W2005021430 creator A5028403057 @default.
• W2005021430 creator A5044232944 @default.
• W2005021430 creator A5045425111 @default.
• W2005021430 creator A5066793063 @default.
• W2005021430 creator A5076292783 @default.
• W2005021430 creator A5079185993 @default.
• W2005021430 date "2014-11-01" @default.
• W2005021430 modified "2023-10-14" @default.
• W2005021430 title "Outcomes of Proton Therapy for Patients With Functional Pituitary Adenomas" @default.
• W2005021430 cites W1946116870 @default.
• W2005021430 cites W1973059597 @default.
• W2005021430 cites W1977055483 @default.
• W2005021430 cites W1999189079 @default.
• W2005021430 cites W2000804718 @default.
• W2005021430 cites W2002070825 @default.
• W2005021430 cites W2002724432 @default.
• W2005021430 cites W2007956690 @default.
• W2005021430 cites W2020395900 @default.
• W2005021430 cites W2024424969 @default.
• W2005021430 cites W2025188641 @default.
• W2005021430 cites W2037931723 @default.
• W2005021430 cites W2043398400 @default.
• W2005021430 cites W2045171408 @default.
• W2005021430 cites W2047245583 @default.
• W2005021430 cites W2052939025 @default.
• W2005021430 cites W2079341064 @default.
• W2005021430 cites W2093010614 @default.
• W2005021430 cites W2093504923 @default.
• W2005021430 cites W2100396774 @default.
• W2005021430 cites W2127400392 @default.
• W2005021430 cites W2137715266 @default.
• W2005021430 cites W2140025941 @default.
• W2005021430 cites W2156492466 @default.
• W2005021430 cites W2157482119 @default.
• W2005021430 cites W2161273855 @default.
• W2005021430 cites W2166601702 @default.
• W2005021430 cites W2171986320 @default.
• W2005021430 cites W2406886408 @default.
• W2005021430 cites W4236514138 @default.
• W2005021430 cites W4246817849 @default.
• W2005021430 doi "https://doi.org/10.1016/j.ijrobp.2014.06.068" @default.
• W2005021430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25194666" @default.
• W2005021430 hasPublicationYear "2014" @default.
• W2005021430 type Work @default.
• W2005021430 sameAs 2005021430 @default.
• W2005021430 citedByCount "85" @default.
• W2005021430 countsByYear W20050214302014 @default.
• W2005021430 countsByYear W20050214302015 @default.
• W2005021430 countsByYear W20050214302016 @default.
• W2005021430 countsByYear W20050214302017 @default.
• W2005021430 countsByYear W20050214302018 @default.
• W2005021430 countsByYear W20050214302019 @default.
• W2005021430 countsByYear W20050214302020 @default.
• W2005021430 countsByYear W20050214302021 @default.
• W2005021430 countsByYear W20050214302022 @default.
• W2005021430 countsByYear W20050214302023 @default.
• W2005021430 crossrefType "journal-article" @default.
• W2005021430 hasAuthorship W2005021430A5001528733 @default.
• W2005021430 hasAuthorship W2005021430A5003790985 @default.
• W2005021430 hasAuthorship W2005021430A5009874528 @default.
• W2005021430 hasAuthorship W2005021430A5017047283 @default.
• W2005021430 hasAuthorship W2005021430A5022118831 @default.
• W2005021430 hasAuthorship W2005021430A5028403057 @default.
• W2005021430 hasAuthorship W2005021430A5044232944 @default.
• W2005021430 hasAuthorship W2005021430A5045425111 @default.
• W2005021430 hasAuthorship W2005021430A5066793063 @default.
• W2005021430 hasAuthorship W2005021430A5076292783 @default.
• W2005021430 hasAuthorship W2005021430A5079185993 @default.
• W2005021430 hasConcept C126322002 @default.
• W2005021430 hasConcept C141071460 @default.
• W2005021430 hasConcept C197934379 @default.
• W2005021430 hasConcept C2777428134 @default.
• W2005021430 hasConcept C2777433750 @default.
• W2005021430 hasConcept C2777793932 @default.
• W2005021430 hasConcept C2778491484 @default.
• W2005021430 hasConcept C2779244869 @default.
• W2005021430 hasConcept C2780387249 @default.
• W2005021430 hasConcept C2984496839 @default.
• W2005021430 hasConcept C2989005 @default.
• W2005021430 hasConcept C509974204 @default.
• W2005021430 hasConcept C526584372 @default.
• W2005021430 hasConcept C71315377 @default.
• W2005021430 hasConcept C71924100 @default.
• W2005021430 hasConceptScore W2005021430C126322002 @default.
• W2005021430 hasConceptScore W2005021430C141071460 @default.
• W2005021430 hasConceptScore W2005021430C197934379 @default.
• W2005021430 hasConceptScore W2005021430C2777428134 @default.
• W2005021430 hasConceptScore W2005021430C2777433750 @default.
• W2005021430 hasConceptScore W2005021430C2777793932 @default.
• W2005021430 hasConceptScore W2005021430C2778491484 @default.
• W2005021430 hasConceptScore W2005021430C2779244869 @default.

• next